TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

June 30, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Trivalent inactivated influenza vaccine

Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose \[60 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.

BIOLOGICAL

Trivalent inactivated influenza vaccine

Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® \[15 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.

Trial Locations (1)

52242-2600

University of Iowa - Vaccine Research & Education Unit, Iowa City

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01436370 - TIV and High Dose TIV in Subjects With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter